DRI Capital Raises U.S. $1.45 Billion for Drug Royalty III

DRI Capital Raises U.S. $1.45 Billion for Drug Royalty III

Firm Surpasses U.S. $1 Billion Target with Third Global Healthcare Royalty Fund

TORONTO & NEW YORK, Sep 09, 2013 (BUSINESS WIRE) -- DRI Capital, a pioneer and global leader in the acquisition of healthcare royalties, today announced the final closing of its U.S. $1.45 billion Drug Royalty III private equity fund (the "Fund"). With available debt, the Fund gives DRI U.S. $3 billion of purchasing power. DRI will use the Fund to continue to execute on its strategy of acquiring royalties from global pharmaceutical and biotechnology companies, research institutions, universities, and inventors located worldwide.

Founded in 1992 as Drug Royalty Corporation, DRI Capital is the oldest and the largest healthcare royalty private equity fund manager in the world. DRI, through its Drug Royalty managed funds, has acquired more than forty international life sciences royalty streams on such leading products as Cubicin, Enbrel, Myozyme, Remicade, Sensipar, Soliris, Stelara, Simponi, Synagis, Tysabri and Xolair, among many others over its 21 year history.

Behzad Khosrowshahi, DRI President and CEO, said, "We are grateful for the commitment shown by investors, which include public and corporate pension plans, university endowments, charitable foundations, family offices and financial institutions located globally. We have a competitive cost of capital, and we look forward to investing in royalty streams on a variety of differentiated healthcare products over the next several years, including product candidates in Phase 3 of clinical development. We have a long track record of working with royalty holders to creatively structure transactions, and our team is excited to do more deals in the global life sciences community."

Atlantic-Pacific Capital was the global placement agent and Akin Gump Strauss Hauer & Feld was the legal counsel for Drug Royalty III.

About DRI Capital: DRI Capital, a pioneer and global leader in healthcare royalty investing, was established in 1992 as Drug Royalty Corporation to purchase royalty streams on approved and clinical stage pharmaceutical products. The raise of Drug Royalty III in 2013 follows the successful raises of Drug Royalty II in 2010 (U.S. $926 million of equity commitments including U.S. $701 million for Drug Royalty II and U.S. $225 million in equity for Drug Royalty II Co-Investment Fund), and Drug Royalty I in 2006 (U.S. $240 million in equity and U.S. $560 million in debt). Headquartered in Toronto, DRI is a fully integrated team of 30 investment professionals with deep life sciences industry expertise drawn from a variety of disciplines. Please visit www.dricapital.com.


        Media Contact: 
        For DRI Capital Inc. 
        Paul Kidwell, 617-680-1088 
        [email protected] 
        Investor Contacts: 
        Atlantic-Pacific Capital, Inc. 
        Alex Leykikh, 203-862-9182 
        [email protected] 
        DRI Capital Inc. 
        Mary Chang, 416-324-5741 
        [email protected]

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.